financetom
Business
financetom
/
Business
/
Nippon Steel executive to visit U.S. to meet stakeholders of U.S. Steel deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nippon Steel executive to visit U.S. to meet stakeholders of U.S. Steel deal
May 20, 2024 8:00 AM

, TOKYO (Reuters) -Japan's Nippon Steel said on Saturday its vice chairman, Takahiro Mori, a key negotiator for its planned purchase of U.S. Steel, will travel to the United States next week to meet stakeholders as part of continued efforts to complete the deal.

A spokesperson for Nippon Steel in Tokyo said Mori will visit the United States to continue dialogues with various stakeholders of the deal to gain a better understanding. She declined to give further details such as who Mori will be meeting with and how long he will stay in the U.S.

U.S. Steel deferred to the Japanese counterpart for comment.

In December, Nippon Steel offered nearly $15 billion to take over U.S. Steel, drawing resistance from both Democratic President Joe Biden and Republican former President Donald Trump, as well as the United Steelworkers (USW) union.

To win support from the USW, Nippon Steel has pledged to move its U.S. headquarters to Pittsburgh, Pennsylvania, where U.S. Steel is based, offering commitments on job security and additional investments if the deal goes through.

Bloomberg reported on Friday in the U.S. that Mori will travel to Pittsburgh next week to meet with local staff and elected officials, citing people briefed on the matter.

The Japanese steelmaker expects to close the deal in the second half of 2024, compared with its prior deadline of the second to third quarter, after the U.S. Department of Justice sought more details and materials in an antitrust review. The European Commission has already approved the deal.

Despite mounting opposition, an overwhelming majority of U.S. Steel shareholders voted in favor of the deal in April.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Impinj Insider Sold Shares Worth $1,884,080, According to a Recent SEC Filing
Impinj Insider Sold Shares Worth $1,884,080, According to a Recent SEC Filing
Sep 2, 2025
03:31 AM EDT, 09/02/2025 (MT Newswires) -- Chris Diorio, Director, Chief Executive Officer, on August 28, 2025, sold 10,000 shares in Impinj ( PI ) for $1,884,080. Following the Form 4 filing with the SEC, Diorio has control over a total of 555,471 common shares of the company, with 356,109 shares held directly and 199,362 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1114995/000141588925023326/xslF345X05/form4-08292025_110828.xml...
Atlassian Insider Sold Shares Worth $1,363,035, According to a Recent SEC Filing
Atlassian Insider Sold Shares Worth $1,363,035, According to a Recent SEC Filing
Sep 2, 2025
03:32 AM EDT, 09/02/2025 (MT Newswires) -- Scott Farquhar, 10% Owner, Director, on August 29, 2025, sold 7,665 shares in Atlassian ( TEAM ) for $1,363,035. Following the Form 4 filing with the SEC, Farquhar has control over a total of 160,965 Class A common shares of the company, with 160,965 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650372/000156218025006045/xslF345X05/primarydocument.xml ...
NIO Reports Increase in August Vehicle Deliveries
NIO Reports Increase in August Vehicle Deliveries
Sep 2, 2025
03:31 AM EDT, 09/02/2025 (MT Newswires) -- NIO (NIO) said Monday it delivered 31,305 vehicles in August, up 55.2% year-over-year. Cumulative deliveries reached 838,036 as of the end of last month, the company said. ...
Zai Lab Secures Hong Kong Medical Regulator Approval for Cervical Cancer Treatment
Zai Lab Secures Hong Kong Medical Regulator Approval for Cervical Cancer Treatment
Sep 2, 2025
03:53 AM EDT, 09/02/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said late Monday that the Hong Kong Department of Health has approved Tivdak for the treatment of adults with recurrent or metastatic cervical cancer. The drug is currently under regulatory review in China, the company said. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved